SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) February 27, 1998
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On February 27, 1998 Biocontrol Technology, Inc.
(NASDAQ:BICO) announced that it has received a signed letter of
intent from a distributor in England to market its Diasensor 1000
noninvasive glucose sensor in the United Kingdom and has
submitted the Technical File for the CE Mark to its Notified
Body, TUV Rheinland Product Safety GmbH, Germany, to allow
marketing the sensor in the European Union (EU).
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired - Not
Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - Press Release.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
CEO
DATED: February 27, 1998
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Release: Immediate
For More Information, Call:
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.279.9455 phone
1.412.279.9690 fax 1.412.279.9447 fax
BIOCONTROL RECEIVES LETTER OF INTENT FOR DISTRIBUTION IN THE UK
AND SUBMITS TECHNICAL FILE FOR CE MARK
Pittsburgh, PA - February 27, 1998 - Biocontrol
Technology, Inc. (Nasdaq:BICO) announced that it has received a
signed letter of intent from a distributor in England to market
its Diasensor 1000 noninvasive glucose sensor in the United
Kingdom and has submitted the Technical File for the CE Mark to
its Notified Body, TUV Rheinland of North America, Inc., to allow
marketing of the sensor in the European Union (EU).
Because the submission of the Technical File, which
will require some additional information, is the final step in
obtaining the CE Mark, the distributor, with extensive experience
in development, manufacture, and sales of products for diabetic
use, will come to Biocontrol within the next two weeks to
conclude a distribution agreement. Further details will be
released once the agreement has been finalized.
When achieved, the CE Mark on the Diasensor will
signify that the product meets the mandatory health and safety
requirements to be marketed in the 15-member European Union (EU)
with a diabetic population of approximately 15 million. The first
two steps in obtaining the CE Mark were completed by the Company
in October 1997 and January 1998 resulting in ISO 9001
registration for its Indiana, PA manufacturing and product
development facilities.
Biocontrol Technology, Inc. (www.bico.com) has its
corporate offices in Pittsburgh, PA and is involved in the
development and manufacture of biomedical devices and
environmental products.
